← feed

Is NCT02252263 results overdue?

Yes — results are overdue. Primary completion was 2017-10-10; the FDAAA-801 reporting deadline (2018-10-10) passed 2811 days ago and no results are posted on ClinicalTrials.gov.

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

NCT IDNCT02252263 ↗
SponsorBristol-Myers Squibb (INDUSTRY)
Public issuerBRISTOL MYERS SQUIBB CO — BMY (CIK 0000014272) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-10-10 (ACTUAL)
Reporting deadline2018-10-10 (completion + 365d)
Days overdue2811
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 9a74e28f54254fd0… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02252263. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →